CAR-T Cell Therapy: China's Approved Pipeline
For international patients facing relapsed or refractory blood cancers — and, increasingly, selected solid tumours — China now offers a commercial CAR-T pipeline spanning multiple targets and indications. Understanding which products are approved, what they treat, and how list prices compare with the United States is often the first practical step before requesting a structured eligibility review.
This article covers:
- China's NMPA-approved CAR-T products by target and indication
- Approximate list prices in China and how they compare with US drug costs
- Why China's pipeline is relevant for international patients after relapse
- How to match a product class to lymphoma, myeloma, ALL, or solid-tumour cases
- What to do next: remote MDT case review before travel
Quick Answer
China has multiple NMPA-approved autologous CAR-T products targeting CD19 (lymphoma and adult B-ALL), BCMA (multiple myeloma), and CLDN18.2 (gastric/GEJ adenocarcinoma). Publicly disclosed China product list prices for the main commercial brands are typically CNY 990,000–1,290,000 per dose (roughly USD 135,000–180,000 at mid-2026 exchange rates) — substantially below 2025 US wholesale acquisition costs (WAC) for FDA-approved CAR-T products, which cluster around about USD 460,000–595,000 for the drug alone. Product fit, centre experience, and full-episode medical cost still matter as much as the headline price. International patients usually begin with a remote case review before deciding whether travel for CAR-T in China is appropriate.
Pricing sources and limits (as of mid-2026)
China figures below reflect publicly reported manufacturer list / launch prices (for example: Yikaida CNY 1.20M; Carteyva CNY 1.29M; Fucaso CNY 1.166M; Saikaize CNY 1.15M; Yuanruida CNY 999,000; Satri-cel/CT041 CNY 990,000). US figures are 2025 wholesale acquisition costs (WAC) from Micromedex Red Book as summarised in the HMPI 2026 analysis CAR-T Therapy: Escalating Costs in an Expanding Market (e.g. Tecartus USD 462,000; Yescarta ≈ USD 503,580; Abecma ≈ USD 528,312; Breyanzi ≈ USD 531,350; Carvykti ≈ USD 555,310; Kymriah ≈ USD 593,533). WAC is a drug list benchmark — not what every payer pays, and not the full treatment episode. China and US totals usually rise once hospitalization, conditioning, and toxicity management are included. Exchange rates, hospital contracts, and labels change; always verify current pricing with the treating centre.
Why China's CAR-T Pipeline Matters for International Patients
In the United States and much of Western Europe, CAR-T access is often constrained by high product prices, insurance barriers, and limited slot availability. China has built a parallel commercial pathway: several domestically approved products, active manufacturing capacity, and haematology centres experienced in managing cytokine release syndrome (CRS) and neurotoxicity (ICANS).
Broader product choice
Multiple CD19 and BCMA products — plus a CLDN18.2 solid-tumour CAR-T — give clinicians more matching options by disease and prior therapy.
Lower list-price band
China manufacturer list prices for major approved products are commonly roughly one-third of 2025 US CAR-T WAC levels for comparable target classes.
Practical access pathway
International patients can often start with remote MDT review, then plan leukapheresis and infusion only if eligibility is confirmed.
Lower cost alone does not make CAR-T appropriate. The medically useful question is whether a specific China-approved product matches the patient's diagnosis, antigen expression, prior lines of therapy, and organ fitness — and whether a centre can deliver the full pathway safely. That is the role of a structured online MDT consultation before travel.
NMPA-Approved CAR-T Products: Target, Indication, and Price
The table-style overview below groups the main commercial products international families ask about. Brand names are the China trade names; generic names help match to international literature. For disease-specific eligibility detail, see our guides on CAR-T for lymphoma and CAR-T for multiple myeloma.
Yikaida (奕凯达)
Axicabtagene ciloleucel / 阿基仑赛 (axi-cel) · Fosun Kite (复星凯特)
Indication: Adult r/r large B-cell lymphoma after ≥2 prior systemic lines; also approved in China for adult LBCL that is refractory to first-line immuno-chemotherapy or relapses within 12 months of first-line therapy
Approx. China list price
CNY 1,200,000 / dose
≈ USD 165,000–170,000 (FX-dependent)
US class comparison
US same product class: Yescarta (axi-cel) — 2025 WAC about USD 503,580 (drug list / WAC, not full episode)
Carteyva (倍诺达)
Relmacabtagene autoleucel / 瑞基奥仑赛 (relma-cel) · JW Therapeutics (药明巨诺)
Indication: Adult r/r large B-cell lymphoma after ≥2 prior systemic lines; adult refractory or within-24-month relapsed follicular lymphoma after ≥2 prior systemic lines; adult r/r mantle cell lymphoma after ≥2 prior systemic lines including a BTK inhibitor
Approx. China list price
CNY 1,290,000 / dose
≈ USD 175,000–180,000 (FX-dependent)
US class comparison
US CD19 lymphoma CAR-T WAC examples (2025): Yescarta ≈ USD 503,580; Breyanzi ≈ USD 531,350; Tecartus ≈ USD 462,000
Yuanruida (源瑞达)
Inaticabtagene autoleucel / 纳基奥仑赛 · Juventas (合源生物)
Indication: Adult relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Approx. China list price
CNY 999,000 / dose
≈ USD 135,000–140,000 (FX-dependent)
US class comparison
US ALL CAR-T WAC example (2025): Kymriah (tisagenlecleucel) ≈ USD 593,533
Fucaso (福可苏)
Equecabtagene autoleucel / 伊基奥仑赛 (eque-cel) · IASO Bio / Innovent (驯鹿生物 / 信达生物)
Indication: Adult relapsed/refractory multiple myeloma after ≥3 prior lines including a proteasome inhibitor and an immunomodulatory agent
Approx. China list price
CNY 1,166,000 / dose
≈ USD 160,000–165,000 (FX-dependent)
US class comparison
US BCMA CAR-T WAC examples (2025): Abecma ≈ USD 528,312; Carvykti ≈ USD 555,310
Saikaize (赛恺泽)
Zevorcabtagene autoleucel / 泽沃基奥仑赛 (zevor-cel) · CARsgen / Huadong Medicine (科济药业 / 华东医药)
Indication: Adult relapsed/refractory multiple myeloma after ≥3 prior lines of therapy, including at least one proteasome inhibitor and one immunomodulatory agent
Approx. China list price
CNY 1,150,000 / dose
≈ USD 155,000–160,000 (FX-dependent)
US class comparison
US BCMA CAR-T WAC examples (2025): Abecma ≈ USD 528,312; Carvykti ≈ USD 555,310
Carvykti (卡卫荻)
Ciltacabtagene autoleucel / 西达基奥仑赛 (cilta-cel) · Legend Biotech / Johnson & Johnson (传奇生物 / 强生)
Indication: Adult relapsed/refractory multiple myeloma after prior therapy including a proteasome inhibitor and an immunomodulatory agent (confirm current China label)
Approx. China list price
China commercial list price less consistently disclosed publicly — verify with treating centre
Confirm current hospital quote
US class comparison
US Carvykti (same molecule) 2025 WAC about USD 555,310
Satri-cel / CT041 (恺力美)
Satricabtagene autoleucel / 舒瑞基奥仑赛 · CARsgen (科济药业)
Indication: CLDN18.2-positive, HER2-negative advanced gastric / gastroesophageal junction adenocarcinoma after failure of at least second-line systemic therapy
Approx. China list price
CNY 990,000 / dose (company-disclosed at launch, June 2026)
≈ USD 135,000–140,000 (FX-dependent)
US class comparison
No FDA-approved solid-tumour CAR-T equivalent as of mid-2026
Not sure which China-approved CAR-T product fits this case?
A structured case review with Chinese haematology or oncology specialists can match diagnosis, prior therapy, and antigen data to the relevant approved product class — and clarify whether travel for CAR-T evaluation is appropriate.
Request a CAR-T case reviewChina vs United States: What the Price Gap Usually Looks Like
Families often compare a single number. A clearer comparison separates product list price from full treatment-episode cost.
| Market | Approx. product list price | What families should note |
|---|---|---|
| China (NMPA) | CNY 990,000–1,290,000 / dose (≈ USD 135,000–180,000, FX-dependent) | Public manufacturer list / launch prices for major brands; full episode usually higher than drug list alone |
| United States (FDA) | About USD 460,000–595,000 WAC (2025) drug list / WAC, not full episode | Examples: Yescarta ≈ USD 503,580; Carvykti ≈ USD 555,310; Kymriah ≈ USD 593,533. Hospital care can raise total episode cost further |
For a fuller breakdown of what sits around the drug price — conditioning, hospitalization, CRS/ICANS management, and follow-up — see our dedicated guide on CAR-T cost in China for international patients. The practical takeaway for many families is not that China is “cheap,” but that an approved CAR-T pathway may be financially reachable when a US or European quote is not.
How to Read the Pipeline by Disease
Large B-cell lymphoma / follicular / mantle cell
Start with CD19 products (Yikaida or Carteyva). Exact choice depends on histology, prior lines, and centre formulary. Relma-cel (Carteyva) currently has the broader China label set across LBCL, FL, and MCL.
Adult B-cell ALL
Yuanruida (inaticabtagene) is the dedicated adult r/r B-ALL commercial option in the China pipeline. Pediatric ALL pathways may involve different programmes or trial access and need separate specialist review.
Multiple myeloma
Three BCMA products (Fucaso, Saikaize, Carvykti) create meaningful choice after proteasome inhibitor and IMiD exposure. Prior BCMA-targeted therapy, organ function, and manufacturing logistics influence selection.
Gastric / GEJ adenocarcinoma (CLDN18.2+)
Satri-cel / CT041 is the solid-tumour entry. Antigen confirmation and prior therapy history are essential. See our dedicated CT041 approval guide for clinical context.
For Claudin18.2-positive gastric disease, read the dedicated article on CT041 (Satri-Cel) NMPA approval. For the operational pathway after a product is selected, see the CAR-T process and timeline for international patients.
China's Practical Advantages for International Patients
Families comparing countries usually weigh four practical factors. China is often competitive on each of them for selected relapsed blood cancers — provided the medical fit is real.
- Multiple approved products in the same target class (especially BCMA for myeloma), which can improve scheduling and matching flexibility
- Product list prices that are commonly far below US FDA-approved CAR-T drug list prices
- Haematology centres with established protocols for managing CRS and ICANS after autologous CAR-T
- A remote-first evaluation model: records review and MDT opinion before committing to flights, leukapheresis, or manufacturing
- An expanding label landscape that now includes a solid-tumour CAR-T option (CLDN18.2) not yet matched by an FDA-approved equivalent
What China does not offer is a guarantee of remission, a one-size-fits-all product, or a substitute for local treating-physician judgment. ChinaMed Waypoint coordinates specialist review and logistics; clinical decisions remain with the treating haematology or oncology team. Explore coordination options via our CAR-T cell therapy coordination service and the CAR-T & Cell Therapy hub.
What International Families Should Do Next
If a China-approved CAR-T product may be relevant, the most efficient sequence is usually:
Assemble records
Pathology with target antigen data (CD19 / BCMA / CLDN18.2 as relevant), prior regimens and responses, recent imaging, organ-function labs, and performance status.
Request remote MDT review
Chinese specialists assess whether an approved product class fits, what additional testing is needed, and whether travel is medically appropriate now.
Compare product and centre options
If eligible, clarify which commercial product, which hospital programme, manufacturing timeline, and estimated full-episode cost.
Decide on travel only after fit is clear
Leukapheresis and infusion planning should follow medical confirmation — not the other way around.
Related Guides
How Much Does CAR-T Cost in China?
Full-episode cost structure, what is included beyond the drug list price, and China vs US comparison.
CAR-T Process & Timeline for International Patients
Step-by-step pathway from remote eligibility review through leukapheresis, manufacturing, infusion, and monitoring.
CT041 (Satri-Cel): Solid-Tumour CAR-T Approval
Deep dive on China's CLDN18.2 CAR-T for gastric and GEJ adenocarcinoma — the solid-tumour entry in the pipeline.
Frequently Asked Questions
How many CAR-T products are approved in China?
As of mid-2026, China's National Medical Products Administration (NMPA) has approved multiple autologous CAR-T products spanning CD19 (lymphoma and adult B-ALL), BCMA (multiple myeloma), and CLDN18.2 (gastric/GEJ adenocarcinoma). The exact commercial catalogue at a given hospital can change as labels expand and new products launch, so product availability should be confirmed during case review.
How do China CAR-T prices compare with the United States?
Publicly disclosed China manufacturer list prices for major approved CAR-T products are typically CNY 990,000–1,290,000 per dose (roughly USD 135,000–180,000 depending on exchange rate). By comparison, 2025 US wholesale acquisition costs (WAC) for FDA-approved CAR-T products are generally around USD 460,000–595,000 for the drug alone — for example Yescarta ≈ USD 503,580, Carvykti ≈ USD 555,310, and Kymriah ≈ USD 593,533. Real-world US episode costs are often higher still once hospital care is included. China full-episode costs also exceed the drug list price, but the product-price gap versus the US remains large.
Which cancers can currently be treated with approved CAR-T in China?
Approved commercial indications primarily cover relapsed/refractory large B-cell lymphoma (including selected second-line LBCL for Yikaida), follicular lymphoma, mantle cell lymphoma, adult B-cell ALL, relapsed/refractory multiple myeloma, and — with CT041/satri-cel — Claudin18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma after at least second-line failure. Eligibility always depends on exact label criteria, prior treatment lines, antigen expression, and patient fitness.
Can international patients access these China-approved CAR-T products?
Yes, international patients can often be evaluated at designated Chinese haematology or oncology centres that administer NMPA-approved CAR-T products. Access depends on clinical eligibility, product-specific criteria, hospital capacity, and logistics. A remote multidisciplinary case review is the usual first step before any travel decision.
Is a lower price the only reason to consider CAR-T in China?
No. Cost is an important factor, but it is not the only one. Families should also evaluate indication fit, which product matches the disease and prior therapy, centre experience with CRS/ICANS management, manufacturing timelines, and whether travel is medically appropriate. A structured case review helps separate product fit from price comparison.
Medical disclaimer
ChinaMed Waypoint is a coordination service, not a medical provider. Nothing in this article constitutes medical advice or a promise of access, price, or clinical outcome. CAR-T product selection, eligibility, and treatment decisions must be made by qualified haematologists or oncologists based on the patient's complete records. List prices and US comparisons are approximate public figures and do not predict an individual patient's final invoice.
Ask Whether a China-Approved CAR-T Product Fits
An online MDT consultation with a Chinese haematology or oncology team can review existing records, map the case to an approved product class, and clarify next steps — including whether travel for CAR-T evaluation is warranted — without requiring a flight first.
For relapsed lymphoma, myeloma, adult B-ALL, and selected solid-tumour CAR-T questions — start with records, not a booking.